Programs

Home/Programs

Day 1 : Oct 08,2024
Day 1 Day 2 Day 3
Download
Keynote Speakers
Biograph:

24    years of experience in Health Care Industry, working with Globe multinational companies in 3 different markets (Africa, middle East Turkey, and Asia Pacific) with multinational corporation.  He recived Biomedical Engineering with Excellent Honours , also received MIBA (Master International Business Administration) from ESLSCA France @ Strategy + Marketing
Certified from   ISRRT & BRACCO Education Licensing for Radiology Imaging certified. Certified Lean Six Sigma for management (green belt) . Currently Business development manager UNILABS/Tibbiyah SAUDI ARABIA ,  sever experience at Medical  Imaging / oncology Centres as a Consultant to improve ROI, Clinical outcome, increase operation efficiency, patient’s workflow optimization and control/reduced cost. Expert in Cardiology / Neurology and Oncology practice at hospital landscape.  

Abstract:

Radiomics and artificial intelligence (AI) are revolutionizing the field of medical imaging, offering unprecedented opportunities for enhanced diagnosis, prognosis, and treatment planning. This talk will explore the transformative impact of these technologies on clinical practice and research. Radiomics involves the extraction of quantitative features from medical images, enabling the conversion of visual data into high-dimensional, mineable data. These features can reveal underlying pathophysiological processes that are not discernible to the naked eye, leading to more accurate and personalized patient care. By integrating radiomics with AI, particularly machine learning algorithms, we can develop predictive models that improve diagnostic accuracy and patient outcomes. AI in imaging leverages deep learning techniques to analyze vast amounts of data, automating the detection and characterization of abnormalities. This capability not only enhances the efficiency and accuracy of radiological interpretations but also addresses the growing demand for imaging services in healthcare systems. AI algorithms can assist in detecting diseases at earlier stages, optimizing treatment plans, and monitoring disease progression with greater precision. The synergy between radiomics and AI holds the promise of advancing precision medicine. This talk will highlight key developments in the field, including the application of AI in oncological imaging for tumor characterization, the prediction of treatment responses, and the assessment of disease progression. Furthermore, it will address the challenges and future directions in implementing these technologies, such as data standardization, validation, and integration into clinical workflows. In conclusion, the fusion of radiomics and AI in medical imaging is set to revolutionize healthcare, providing clinicians with powerful tools for better patient management. This talk aims to provide an overview of the current landscape, recent advancements, and future prospects of radiomics and AI in imaging, underscoring their potential to enhance patient care and outcomes.
 
Biography:

Dr. Tom Chittenden, a GIGA Society Fellow with over 25 years of experience, is Chief Scientific Officer at BullFrog AI. He oversees global scientific operations and leads the development of the bfLEAPTM technology platform. This platform embodies cutting-edge advancements in causal AI and scientific machine learning, offering innovative solutions to complex challenges in healthcare. Additionally, Dr. Chittenden holds an Honorary Professorship at Queen Mary University of London's Digital Environment Research Institute, contributing to cutting-edge research in data science.

Abstract:
Recent advancements in high-throughput genomic sequencing technologies have enabled the acquisition of vast amounts of biological data, offering unprecedented insights into the molecular basis of human diseases. Despite these advancements, understanding the causal relationships underlying disease pathogenesis remains a significant challenge. In this seminar, we will explore the integration of causal inference techniques and scientific machine learning (SciML) approaches in biomedical research. By harnessing novel computational strategies, such as causal AI, we aim to decipher complex biological mechanisms and uncover actionable insights for drug target discovery and clinical trial optimization. Through case studies and practical examples, we will demonstrate the transformative potential of these methodologies in accelerating the development and repositioning of more effective therapeutic interventions. Join us as we delve into the intersection of data science, causal reasoning, and biomedical innovation, paving the way for personalized medicine and improved patient outcomes.
Speaker Sessions
Biography:

Priya Hays, M.S., Ph.D. is an accomplished science writer, having written and published five books as well as having authored over twenty publications in journals as varied as the Bulletin of Science, Technology and Society, L’Esprit Createur, Interdisciplinary Literary Studies, Genetics in Medicine, Journal of Clinical Investigation and Studies, and Preventive Medicine, Epidemiology and Public Health and Journal of Clinical and Translational Research.  The Second Edition of her book Advancing Healthcare Through Personalized Medicine received critical acclaim, and she served as Guest Editor for a volume on cancer immunotherapies in the Cancer Treatment and Research series, both published by Springer Nature.  Her work has been featured is Open Access Government UK and Research Features UK. Her latest book is a compilation of papers entitled “A Dialectical Mind: Essays in Literary Studies, Science and Medicine” published by Eliva Press. She completed her postdoctoral research fellowship in the Division of Hematology/Oncology, Department of Medicine, at Dartmouth Medical School. She has an A.B. with Honors from Dartmouth College in Biochemistry and Comparative Literature, an M.S. in Genetics from the University of California, Davis, and a Ph.D. in Literature from the University of California, San Diego

Abstract:

Immune checkpoint blockade has evolved in the realm of cancer immunotherapies to become standard of care in front-line settings, as well as in adjuvant and even neoadjuvant settings, especially in immunogenic tumors such as advanced melanoma. However, while many patients respond to these therapies with long-term robust clinical outcomes, there exists a considerable degree of non-responders. Studies have attributed this clinical situation to a number of correlative and causative factors, and a new generation of therapies are being developed to be used alone or in combination with anti-CTLA-4 and anti-PD-1 therapies to improve survival and overall response rates. This talk will discusses the next generation immune checkpoint inhibitors against LAG-3, TIGIT, and TIM-3 and highlights emerging insights into their mechanisms of action. Another approach is the use of tumor infiltrating lymphocytes, discussed in the context of feasibility and randomized trials. These two approaches outlined in this paper explain distinct avenues to address the issue of non-responders and provide ways to circumvent the difficulties they pose for patients and in the clinic. This talk concludes on future directions in the form of reverse translation methods and their use and application for addressing non-responders to immune checkpoint blockade.
Biograph:

Mr. Deven Patel, the CEO, President and Cofounder of Global Institute of Stem Cell Therapy and Research (GIOSTAR) is based in San Diego, California, U.S.A. GIOSTAR was formed with the vision to provide affordable stem cell based therapies to the masses around the world suffering from many incurable degenerative diseases. He was honored with USA Congressional Recognition for his efforts in spreading the advancement of stem cell science around the world.  He was also bestowed upon Asian Heritage Award for his business leadership in the field of stem cell science.  GIOSTAR under the leadership of Mr. Patel has developed several stem cell research and treatment facilities around the globe including USA, Mexico, India, Costa Rica plus few more in near future in China, Thailand, Greece , Bahamas, Dubai and Australia. GIOSTAR, in collaborations with Govt. of Gujarat, India, developing world's largest Stem Cell Treatment Hospital in India.

Abstract:
The life expectancy or longevity is the number of years a person is expected to live. It depends on various factors including genetics, gender, individual life style and socio-economic factors. According to the United Nations, the global life expectancy as of 2023 was 70.8 years for males and 76.0 years for females, for an average of 73.4 years. Longevity, vary significantly by region as well as by country.  Various scientific discoveries in the recent decades, in the area of human health, have contributed towards improvement in longevity.
Biologically, human aging is associated with reduced tissue regeneration, increased degenerative disease, and cancer. Stem cells persist throughout life in numerous mammalian tissues, replacing cells lost to homeostatic turnover, injury, and disease. With the aging process, stem cell function declines in numerous tissues as a result of gate-keeping tumor suppressor expression, DNA damage, changes in cellular physiology, and environmental changes in tissues.  Like all cells, stem cell aging is determined partly by the accumulation of damage over time. Declines in stem cell function during aging can be attributed to telomere shortening, DNA damage, and mitochondrial damage. Mitochondrial activity, tissue growth, and metabolic rates during development can also influence life span and the rates of cellular aging at later stages of life. The criticality of normal mitochondrial function, required for embryonic stem cell proliferation, regulating differentiation, and preventing the emergence of tumorigenic cells during the process of differentiation, was demonstrated by GIOSTAR Chairman Dr Anand Srivastava in his work at UCLA. The author showed that by arresting the mitochondrial function the cell division ability of stem cells were enhanced. This was a significant finding as the role of genes associated with pluripotency were linked to the mitochondrial function. Indirectly, it was observed that aging can be controlled by modulating the mitochondrial function. 
GIOSTAR is the pioneer and leading institute working in area of stem cells and regenerative medicine. Under the scientific leadership of Dr Anand Srivastava, the institute developing and providing the therapeutic interventions harnessing the power of stem cells.
Biograph:

Performance-driven professional with 20 years of experience in the health care and life sciences industry, with a strong focus on Digital Pathology and data sciences. Proven track record in running a global organization and building strategic partnerships with leading Pharma/Biotech companies with focus in oncology. Strong technical background in drug development process, companion diagnostic strategy, business development, genomics, pathology and clinical implementation of tissue and image-based assays. Ability to drive complex strategies forward and guide multi-disciplinary teams to success while managing a global team in a matrix environment. Significant achievements across professional services, product development, operations, and alliance management. Demonstrated success in solving key problems and implementing solutions leading to successful delivery of projects and establishment of partnerships as a trusted advisor, team leader and partner

Abstract: 

At BioAI, we develop world-leading machine learning technology to develop digital biomarker tests for patient selection and screening. The BioAI PredictX platform is capable of ingesting a range of data types, including Digital Pathology, Multiomics and Real-World Evidence. Using multimodal data, state-of-the-art AI methods, and integrated deep learning, we can build predictive and prognostic models across a wide range of therapeutic areas. BioAI has built numerous models that can be used to classify both molecular status and tissue biomarkers directly from H&E slides without the need for additional molecular or IHC testing.  PredictLung, currently in development, is an AI-powered digital test panel for NSCLC patient tumor tissue samples that can predict actionable mutations and biomarkers from H&E stained images.  This test leverages an existing H&E image (available as a standard diagnostic procedure) and is a rapid, generalizable screening test that can help guide therapy selection.
Biograph:

Nardev Ramanathan is an associate research director and leads Lux Research’s coverage of Consumer Health Sciences as part of the CPG team. In this role, Nardev works closely with senior innovation leaders across the globe to guide and shape their corporate innovation strategies around new and emerging consumer health technologies, such as digital biomarkers, digital therapeutics, health wearables, AI in consumer health, and consumer genomics. As one of the senior members of the CPG team, he is also involved in planning the research agenda for the CPG team with other research leaders and more broadly supports cross-functional research related to the intersection between food, nutrition and agricultural innovation impact consumer health, working with subject matter experts across Lux.
Nardev earned his Ph.D. in Clinical Biochemistry from the University of Cambridge on an A*STAR Overseas Ph.D. scholarship. For his doctoral thesis, he identified a novel genetic mutation responsible for a rare inherited disease called lipodystrophy in a patient in the Middle East and went on to elucidate the molecular mechanism underlying the disease. Nardev has authored multiple peer-reviewed publications around metabolic health topics, many of which continue to be highly cited.

Abstract:

Digital biomarkers are emerging as a key technology in health and wellness, opening up new ways to use established sensors for early identification and management of disease. Digital biomarkers are key to personalizing healthcare, in the sense of both maintaining wellness and treating disease. Unlike traditional biomarkers, digital biomarkers provide distinct advantages, in that data can be collected continuously and noninvasively and can be analyzed and processed at scale in combination with other data streams, unlocking deeper insights. Consumers and patients can thus benefit from early diagnostics and timely interventions, and healthcare providers benefit from a more seamless and accessible technology for managing disease. In this presentation, I will delve deeper into what digital biomarkers are, discuss new and emerging opportunities, and share examples of innovative developers making progress in this space.